© 2020 MJH Life Sciences and Neurology Live. All rights reserved.
© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
September 18, 2020
Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.
September 17, 2020
The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.
Two posters presented at MDS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.
September 16, 2020
The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.